AUROPHARMA Aurobindo Pharma Q4 FY26 results (Jan–Mar 2026) and concall
Aurobindo Pharma reported record revenues and EBITDA for both Q4 and full-year FY26, driven by stable volumes and new product launches across businesses. While US formulations saw a decline due to prior year's high gRevlimid sales, Europe achieved a €1 billion revenue milestone. The company is focused on strategic growth levers including biosimilars, CDMO, and expanding its US and domestic businesses, despite facing increased operating costs from Pen-G plant operations and delays in the Lannett acquisition.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 5.6%, net profit up 2.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 +6% | 8,646 +8% | 8,853 +6% |
| EBITDA | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 +7% | 1,773 +12% | 1,750 −1% |
| Net profit | 817 | 846 | 903 | 824 | 848 +4% | 910 +8% | 921 +2% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
